MLchartDataset catalogue

Patent · US2009035351A1 · A1 · US

Bioabsorbable Hypotubes for Intravascular Drug Delivery

(11) Publication number
US2009035351A1
(21) Application number
US-21281708-A
(22) Filing date
2008-09-18
(30) Priority date
2007-07-20
(43) Publication date
2009-02-05
(52) CPC
  • A61F Filters implantable into blood vessels; prostheses; devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents; orthopaedic, nursing or contraceptive devices; fomentation; treatment or protection of eyes or ears; bandages, dressings or absorbent pads; first-aid kits: 2/88, 2/022, 2/82, 2/885, 2250/003, 2250/0035, 2250/0068
(73) Assignee
MEDTRONIC VASCULAR INC
(54) Title
Bioabsorbable Hypotubes for Intravascular Drug Delivery
(57) Abstract

A biodegradable implantable device for delivering a drug to a treatment site includes a biodegradable hypotube defining a lumen and at least one drug disposed within the lumen of the hypotube. At least one drug is released from the lumen upon degradation of the biodegradable hypotube. The lumen may be compartmentalized, each compartment containing a different drug. The hypotube may also include a plurality of pores in fluid communication with the compartments providing different drug release profiles.

Full text
View on Google Patents

Claims (1)

  1. A biodegradable implantable device for delivering a drug to a treatment site comprising: a biodegradable hypotube, the hypotube defining a lumen; and at least one drug disposed within the lumen of the hypotube, wherein the at least one drug is released from the lumen of the biodegradable hypotube. 2. The device of claim 1 wherein the implantable device comprises a stent. 3. The device of claim 2 wherein the stent comprises a plurality of hypotubes, wherein the plurality of hypotubes are in a configuration selected from the group consisting of a helical configuration, a braided configuration, a mesh configuration and a woven configuration. 4. The device of claim 1 wherein the biodegradable material comprising the hypotube comprises a material selected from the group consisting of biodegradable metals, biodegradable metal alloys, biodegradable polymers and combinations thereof. 5. The device of claim 4 wherein the biodegradable polymer is selected from the group consisting of poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(ethylene-vinyl acetate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, fibrin, fibrinogen, cellulose, starch, collagen, hyaluronic acid, poly-N-alkylacrylamides, poly depsi-peptide carbonate, polyethylene-oxide based polyesters, and combinations thereof. 6. The device of claim 1 wherein the lumen includes at least two compartments. 7. The device of claim 6 wherein each of the compartments contains different drugs. 8. The device of claim 7 wherein each of the compartments exhibits different drug release profiles. 9. The device of claim 1 wherein the biodegradable hypotube includes a plurality of pores disposed within a wall of the hypotube, the plurality of pores in fluid communication with the lumen. 10. The device of claim 9 wherein the plurality of pores are plugged with a biodegradable material. 11. The device of claim 10 wherein the biodegradable material plugging the plurality of pores comprises a biodegradable material different than the biodegradable material comprising the hypotube. 12. The device of claim 9 wherein the plurality of pores are spaced along the hypotube to create different drug release profiles at different portions of the implantable device. 13. The device of claim 7 wherein the biodegradable hypotube includes a first plurality of pores disposed within a wall of the hypotube, the first plurality of pores in fluid communication with a first compartment of the lumen and a second plurality of pores disposed within the wall of the hypotube, the second plurality of pores in fluid communication with a second compartment of the lumen. 14. The device of claim 13 wherein a first drug within the first compartment has a first release profile and a second drug in the second compartment has a second release profile. 15. The device of claim 10 wherein the implantable device defines a channel and a majority of the plurality of pores are disposed on a portion of the hypotube in fluid communication with the channel. 16. The device of claim 10 wherein the implantable device defines a channel and a majority of the plurality of pores are disposed on the portion of the hypotube that is in fluid communication with a vessel wall. 17. The device of claim 1 wherein the at least one drug is combined with a biocompatible carrier before the drug is disposed within the lumen of the hypotube. 18. The device of claim 17 wherein the biocompatible carrier comprises a biodegradable material selected from the group consisting of poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(ethylene-vinyl acetate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, fibrin, fibrinogen, cellulose, starch, collagen, hyaluronic acid, poly-N-alkylacrylamides, poly depsi-peptide carbonate, polyethylene-oxide based polyesters, mineral oils, caster oils, ethylene glycol, BHT and combinations thereof. 19. The device of claim 1 wherein the at least one drug is selected from the group consisting of anti-proliferatives, estrogens, chaperone inhibitors, protease inhibitors, protein-tyrosine kinase inhibitors, leptomycin B, peroxisome proliferator-activated receptor gamma ligands (PPARγ), hypothemycin, nitric oxide, bisphosphonates, epidermal growth factor inhibitors, antibodies, proteasome inhibitors, antibiotics, anti-inflammatories, anti-sense nucleotides and transforming nucleic acids. 20. The device of claim 1 wherein the at least one drug is selected from the group consisting of sirolimus (rapamycin), tacrolimus (FK506), everolimus (certican), temsirolimus (CCI-779) and zotarolimus (ABT-578).

Citations (22)

  • US2003105512A1
  • US2004024449A1
  • US2004106984A1
  • US2004133270A1
  • US2004199241A1
  • US2004225347A1
  • US2006053618A1
  • US2006224234A1
  • US2007129786A1
  • US2007156230A1
  • US4886062A
  • US5035891A
  • US5769883A
  • US5957975A
  • US6071305A
  • US6159490A
  • US6206915B1
  • US6306826B1
  • US6491720B1
  • US6645243B2
  • US6758859B1
  • US6926735B2
Record as JSON
{
  "publication_number": "US2009035351A1",
  "country": "US",
  "kind": "A1",
  "title": "Bioabsorbable Hypotubes for Intravascular Drug Delivery",
  "abstract": "A biodegradable implantable device for delivering a drug to a treatment site includes a biodegradable hypotube defining a lumen and at least one drug disposed within the lumen of the hypotube. At least one drug is released from the lumen upon degradation of the biodegradable hypotube. The lumen may be compartmentalized, each compartment containing a different drug. The hypotube may also include a plurality of pores in fluid communication with the compartments providing different drug release profiles.",
  "claims": [
    "1. A biodegradable implantable device for delivering a drug to a treatment site comprising: a biodegradable hypotube, the hypotube defining a lumen; and at least one drug disposed within the lumen of the hypotube, wherein the at least one drug is released from the lumen of the biodegradable hypotube. 2. The device of claim 1 wherein the implantable device comprises a stent. 3. The device of claim 2 wherein the stent comprises a plurality of hypotubes, wherein the plurality of hypotubes are in a configuration selected from the group consisting of a helical configuration, a braided configuration, a mesh configuration and a woven configuration. 4. The device of claim 1 wherein the biodegradable material comprising the hypotube comprises a material selected from the group consisting of biodegradable metals, biodegradable metal alloys, biodegradable polymers and combinations thereof. 5. The device of claim 4 wherein the biodegradable polymer is selected from the group consisting of poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(ethylene-vinyl acetate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, fibrin, fibrinogen, cellulose, starch, collagen, hyaluronic acid, poly-N-alkylacrylamides, poly depsi-peptide carbonate, polyethylene-oxide based polyesters, and combinations thereof. 6. The device of claim 1 wherein the lumen includes at least two compartments. 7. The device of claim 6 wherein each of the compartments contains different drugs. 8. The device of claim 7 wherein each of the compartments exhibits different drug release profiles. 9. The device of claim 1 wherein the biodegradable hypotube includes a plurality of pores disposed within a wall of the hypotube, the plurality of pores in fluid communication with the lumen. 10. The device of claim 9 wherein the plurality of pores are plugged with a biodegradable material. 11. The device of claim 10 wherein the biodegradable material plugging the plurality of pores comprises a biodegradable material different than the biodegradable material comprising the hypotube. 12. The device of claim 9 wherein the plurality of pores are spaced along the hypotube to create different drug release profiles at different portions of the implantable device. 13. The device of claim 7 wherein the biodegradable hypotube includes a first plurality of pores disposed within a wall of the hypotube, the first plurality of pores in fluid communication with a first compartment of the lumen and a second plurality of pores disposed within the wall of the hypotube, the second plurality of pores in fluid communication with a second compartment of the lumen. 14. The device of claim 13 wherein a first drug within the first compartment has a first release profile and a second drug in the second compartment has a second release profile. 15. The device of claim 10 wherein the implantable device defines a channel and a majority of the plurality of pores are disposed on a portion of the hypotube in fluid communication with the channel. 16. The device of claim 10 wherein the implantable device defines a channel and a majority of the plurality of pores are disposed on the portion of the hypotube that is in fluid communication with a vessel wall. 17. The device of claim 1 wherein the at least one drug is combined with a biocompatible carrier before the drug is disposed within the lumen of the hypotube. 18. The device of claim 17 wherein the biocompatible carrier comprises a biodegradable material selected from the group consisting of poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(ethylene-vinyl acetate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, fibrin, fibrinogen, cellulose, starch, collagen, hyaluronic acid, poly-N-alkylacrylamides, poly depsi-peptide carbonate, polyethylene-oxide based polyesters, mineral oils, caster oils, ethylene glycol, BHT and combinations thereof. 19. The device of claim 1 wherein the at least one drug is selected from the group consisting of anti-proliferatives, estrogens, chaperone inhibitors, protease inhibitors, protein-tyrosine kinase inhibitors, leptomycin B, peroxisome proliferator-activated receptor gamma ligands (PPARγ), hypothemycin, nitric oxide, bisphosphonates, epidermal growth factor inhibitors, antibodies, proteasome inhibitors, antibiotics, anti-inflammatories, anti-sense nucleotides and transforming nucleic acids. 20. The device of claim 1 wherein the at least one drug is selected from the group consisting of sirolimus (rapamycin), tacrolimus (FK506), everolimus (certican), temsirolimus (CCI-779) and zotarolimus (ABT-578)."
  ],
  "cpc": [
    "A61F 2/88",
    "A61F 2/022",
    "A61F 2/82",
    "A61F 2/885",
    "A61F 2250/003",
    "A61F 2250/0035",
    "A61F 2250/0068"
  ],
  "assignees": [
    "MEDTRONIC VASCULAR INC"
  ],
  "filing_date": "2008-09-18",
  "publication_date": "2009-02-05",
  "priority_date": "2007-07-20",
  "application_number": "US-21281708-A",
  "family_id": "41334514",
  "citations": [
    "US2003105512A1",
    "US2004024449A1",
    "US2004106984A1",
    "US2004133270A1",
    "US2004199241A1",
    "US2004225347A1",
    "US2006053618A1",
    "US2006224234A1",
    "US2007129786A1",
    "US2007156230A1",
    "US4886062A",
    "US5035891A",
    "US5769883A",
    "US5957975A",
    "US6071305A",
    "US6159490A",
    "US6206915B1",
    "US6306826B1",
    "US6491720B1",
    "US6645243B2",
    "US6758859B1",
    "US6926735B2"
  ]
}

Record 2,582 of 5,000 in Patents full text (MLC-0201). Request the full dataset.